Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMVP5YE)

• Drug Name: Doxorubicin Drug Info
• Synonyms: doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin
• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 31703
  ChEBI ID: CHEMBL53463
  CAS Number: CAS 23214-92-8
  TTD Drug ID: D07VLY
  VARIDT Drug ID: DR00301
  INTEDE Drug ID: DR0546

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Lysosome	2.57	0.00e+0	115/128 (89.84%)	GAA;HEXA;FUCA1;...
Graft-versus-host disease	2.55	0.00e+0	32/42 (76.19%)	HLA-B;FAS;HLA-F;...
Oxidative phosphorylation	2.41	0.00e+0	93/133 (69.92%)	ATP5F1E;COX8A;NDUFB1;...
Type I diabetes mellitus	2.37	0.00e+0	38/43 (88.37%)	HLA-B;FAS;HLA-F;...
Autoimmune thyroid disease	2.35	0.00e+0	46/53 (86.79%)	HLA-B;FAS;HLA-F;...
Allograft rejection	2.34	0.00e+0	32/38 (84.21%)	HLA-B;FAS;HLA-F;...
Viral myocarditis	2.15	0.00e+0	53/60 (88.33%)	HLA-B;HLA-F;HLA-C;...
Other glycan degradation	2.12	0.00e+0	13/18 (72.22%)	HEXA;FUCA1;AGA;...
Phagosome	2.11	0.00e+0	118/152 (77.63%)	TAP1;HLA-B;HLA-F;...
Fatty acid degradation	2.10	0.00e+0	40/43 (93.02%)	ACSL5;ALDH3A2;ACADVL;...
Valine, leucine and isoleucine degradation	2.06	0.00e+0	42/48 (87.5%)	ABAT;ALDH3A2;ACADM;...
p53 signaling pathway	2.06	0.00e+0	63/73 (86.3%)	DDB2;CDKN1A;FAS;...
Antigen processing and presentation	1.99	0.00e+0	60/78 (76.92%)	TAP1;HLA-B;HLA-F;...
Rheumatoid arthritis	1.96	0.00e+0	78/93 (83.87%)	IL1B;CCL5;HLA-DQA1;...
Arginine and proline metabolism	1.94	0.00e+0	39/50 (78%)	CKB;MAOA;ALDH3A2;...
Cell adhesion molecules	1.92	0.00e+0	118/148 (79.73%)	CADM1;HLA-B;HLA-F;...
Tryptophan metabolism	1.91	0.00e+0	35/42 (83.33%)	MAOA;ALDH3A2;AOC1;...
Staphylococcus aureus infection	1.91	0.00e+0	72/95 (75.79%)	HLA-DQA1;CFB;C2;...
Epstein-Barr virus infection	1.90	0.00e+0	189/202 (93.56%)	DDB2;TAP1;ISG15;...
Herpes simplex virus 1 infection	1.90	0.00e+0	165/498 (33.13%)	TAP1;HLA-B;STAT1;...
Glycosaminoglycan degradation	1.89	0.00e+0	19/19 (100%)	HEXA;GALNS;GNS;...
Fatty acid elongation	1.85	1.57e-3	19/27 (70.37%)	HACD1;ACOT7;HADHB;...
Histidine metabolism	1.83	2.50e-3	16/22 (72.73%)	MAOA;ALDH3A2;ALDH3B1;...
Glutathione metabolism	1.81	3.36e-3	43/57 (75.44%)	GSTM3;GPX3;GPX1;...
Peroxisome	1.80	4.60e-3	72/82 (87.8%)	ACSL5;CROT;MPV17;...
Butanoate metabolism	1.79	4.87e-3	23/28 (82.14%)	ABAT;ALDH5A1;GAD1;...
Hematopoietic cell lineage	1.79	4.69e-3	90/99 (90.91%)	CD9;IL1B;HLA-DQA1;...
Viral protein interaction with cytokine and cytokine re...	1.74	9.52e-3	84/100 (84%)	CXCL13;CXCL10;CCL5;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis	1.74	9.21e-3	20/26 (76.92%)	PIGT;PIGG;PIGF;...
ABC transporters	1.73	9.28e-3	37/45 (82.22%)	TAP1;ABCB6;ABCA1;...
Progesterone-mediated oocyte maturation	-1.85	1.00e-2	75/100 (75%)	CDC25A;RPS6KA2;KIF22;...
Cell cycle	-1.87	8.35e-3	110/124 (88.71%)	STAG2;GADD45B;CDC25A;...
RNA transport	-2.02	0.00e+0	128/186 (68.82%)	RPP30;RPP14;EIF3A;...
Spliceosome	-2.33	0.00e+0	101/150 (67.33%)	FUS;PRPF6;PPIH;...
Ribosome biogenesis in eukaryotes	-2.47	0.00e+0	52/108 (48.15%)	NHP2;FCF1;RPP30;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	0.12uM - 10uM	6H, 24H, 48H	Hide ▲

Bone marrow

Chronic myeloid leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
K-562	CVCL_0004	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Multiple myeloma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
KMS-34	CVCL_1333	Homo sapiens	0.01uM - 2.5uM	24H	Show ▼

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.002uM - 10uM	6H, 24H, 48H	Show ▼
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 2.22uM	24H	Show ▼

Fibrocystic breast disease

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A (Parent)	CVCL_0598	Homo sapiens	1.11uM - 10uM	3H, 6H, 12H, 24H	Show ▼

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 100uM	24H, 48H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.04uM - 100uM	6H, 24H, 48H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.002uM - 10uM	6H, 24H, 48H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.04uM - 10uM	6H, 24H	Show ▼

Lymph node

Burkitt lymphoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
BJAB	CVCL_5711	Homo sapiens	0.01uM - 10uM	3H, 6H, 24H	Show ▼

Diffuse large B-cell lymphoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HBL-1	CVCL_4213	Homo sapiens	0.01uM - 10uM	24H	Show ▼
OCI-Ly10	CVCL_8795	Homo sapiens	0.01uM - 0.66uM	24H	Show ▼
OCI-Ly19	CVCL_8797	Homo sapiens	0.01uM - 0.125uM	24H	Show ▼
OCI-Ly3	CVCL_8796	Homo sapiens	0.01uM - 10uM	24H	Show ▼
TMD8	CVCL_A440	Homo sapiens	0.01uM - 10uM	3H, 6H, 24H	Show ▼

Mantle cell lymphoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MINO	CVCL_4965	Homo sapiens	0.01uM - 10uM	3H, 6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute B-lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
NALM-6	CVCL_0092	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	3H, 6H, 24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
SK-MEL-5	CVCL_0527	Homo sapiens	0.01uM - 0.66uM	24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.04uM - 10uM	24H	Show ▼